{"success":true,"data":{"pressRelease":{"id":"41411","rtpr_id":"nGNX6P6Tzh","ticker":"NANOB","exchange":"Euronext Paris","all_tickers":["NANOB"],"title":"Nanobiotix Announces Launch of Global Follow-On Offering","author":"Globe Newswire","published_at":"2026-05-20T22:19:00.129Z","article_body":"PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX\n(Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a\nlate-clinical stage biotechnology company pioneering physics-based approaches\nto expand treatment possibilities for patients with cancer and other major\ndiseases, announces the launch, subject to market and other conditions, of an\napproximately €75 million global follow-on offering (representing\napproximately $87 million) consisting of (i) a public offering of its American\nDepositary Shares (“ADSs”), each ADS representing one ordinary share,\n€0.03 nominal value per share (each an “Ordinary Share”), of the\nCompany, in the United States (the “U.S. Offering”) and (ii) an offering\nof (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for\nOrdinary Shares (the “PFW”), exclusively addressed to “qualified\ninvestors” in Europe (including France) within the meaning of Article 2(e)\nof Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”),\nand certain other countries (excluding the United States and Canada) (the\n“International Offering”). The U.S. Offering and the International\nOffering are referred to, together, as the “Global Offering”. The number\nof ADSs and Ordinary Shares issued in the Global Offering may be increased in\nthe event of significant demand.\n\nJefferies, TD Cowen and Stifel are acting as global coordinators and joint\nbookrunners for the Global Offering. The Global Offering would be subject to\nan underwriting agreement. The underwriting agreement would not constitute a\nperformance guarantee (garantie de bonne fin) within the meaning of Article L.\n225-145 of the French Commercial Code (Code de commerce).\n\nIn connection with the Global Offering, the Company intends to grant the\nunderwriters for the Global Offering a 30-day option to purchase additional\nADSs, in an amount of up to 15% of the total number of ADSs in the Global\nOffering, on the same terms and conditions, in accordance with delegation\ngranted by the Company’s combined shareholders’ meeting held on May 19,\n2025 (the “Shareholders’ Meeting”) in its 36(th) resolution.\n\nThe Ordinary Shares (including in the form of ADSs) and the PFW to be issued\nin the Global Offering will be issued without preferential subscription rights\nfor existing shareholders by way of a capital increase pursuant to the\ndelegation granted by the Shareholders’ Meeting in its 29(th) resolution.\n\nAll securities to be issued in the Global Offering will be offered by the\nCompany. The Company’s ADSs are listed on the Nasdaq Global Select Market\nunder the ticker symbol “NBTX.” The Company’s Ordinary Shares are listed\non the regulated market of Euronext in Paris (“Euronext”) under the symbol\n“NANO.” The Company does not intend to list the PFW on any domestic or\nforeign securities exchange or nationally recognized trading system.\n\nThe final amount of the Global Offering, the offering price in the U.S.\nOffering in U.S. dollars and the offering price in the International Offering\nin euros, as well as the final number of ADSs, Ordinary Shares and PFW issued\nin the Global Offering will be determined following a book-building process\ncommencing immediately. The Company will announce the results of the Global\nOffering as well as the number and subscription price of the Ordinary Shares,\nADSs and PFW to be issued in the context of the Global Offering as soon as\npracticable after pricing thereof in a subsequent press release.\n\nThe number of securities issued in the Global Offering will be determined by\nthe Company’s Executive Board in accordance with the delegations granted by\nthe Shareholders’ Meeting, pursuant to its 29(t)(h) and 39(th) resolutions.\n\nThe offering price of each Ordinary Share to be issued in the International\nOffering will be in euros and at least equal to the volume weighted average\nprice of the Ordinary Shares on Euronext over the last three trading sessions\npreceding the pricing of the Global Offering (i.e., May 18, May 19 and May 20,\n2026), subject to a maximum 15% discount. The offering price of each ADS in\nthe U.S. Offering will be the U.S. dollars equivalent of the offering price\nper Ordinary Share in euros in the International Offering.\n\nThe subscription price of each PFW to subscribe for one Ordinary Share will be\nin euros and equal to the subscription price per Ordinary Share to be paid on\nthe date of issue of the PFW, minus €0.03 to be paid on the date of exercise\nof the PFW.\n\nEach PFW will allow its holder to subscribe to one Ordinary Share at a price\nof €0.03.\n\nThe PFW are exercisable in cash during a ten-year period from their date of\nissue.\n\nThe PFW are securities giving access to the capital within the meaning of\nArticle L. 228-91 of the French Commercial Code. They will be issued in\ndematerialized form and held in pure registered form (au nominatif pur) in the\nsecurities account opened in the name of the holder thereof in the books of\nthe Company’s account keeper.\n\nNo fractional shares shall be issuable upon the exercise of PFW, provided that\nthe number of shares to be delivered in respect of any exercise of one or more\nPFW pursuant to any exercise notice shall be rounded down to the nearest whole\nmultiple of one share.\n\nIf the Company carries out any of the transactions referred to in Articles L.\n228-99 and L. 228-101 of the French Commercial Code, the rights of holders of\nthe PFW will be maintained in accordance with said articles.\n\nThe PFW will not be admitted to trading on Euronext or on any domestic or\nforeign securities exchange or nationally recognized trading system. The\nshares issued upon the exercise of PFW (the “PFW Shares”) will be held, at\nthe option of the holder, in registered form (au nominatif) or in bearer form\n(au porteur). As soon as they are issued, the PFW Shares will be automatically\nassimilated to the Company’s ordinary shares and will be admitted to trading\non Euronext under the same ISIN number.\n\nThe PFW holders will be grouped automatically for the defense of their common\ninterests in a masse. The masse will act, in part, through a representative\nand, in part, through collective decisions of the holders.\n\nOrdinary Shares (including those underlying ADS) issued in the Global Offering\nwill be subject to an application for admission to trading on Euronext on the\nsame trading line as the existing Ordinary Shares of the Company currently\nlisted on Euronext, under the same ISIN code FR0011341205. The Global Offering\nwill begin immediately following the publication of this press release and is\nexpected to price before the U.S. markets open on May 21, 2026, subject to any\nearly closing of the bookbuilding process. Following pricing of the offering\nin the United States, the trading of Nanobiotix's Ordinary Shares on Euronext\nwill be suspended on the immediately following trading day in Paris from the\nopening of Euronext until the opening of trading of Nanobiotix's ADSs on the\nNasdaq Global Select Market at approximately 3:30 pm (Paris time) / 9:30 a.m.\n(New York time) on such trading day, prior to which Nanobiotix will publish\nthe allocation of share capital to be effective following settlement and\ndelivery of the securities issued in the Global Offering.\n\nThe Company intends to use the net proceeds from the Global Offering as\nfollows:\n* less than 10% to support the development and advancement of JNJ-1900\n(NBTXR3);\n* between 50-60% to advance our Nanoprimer and other platforms; and\n* between 30-40% for general corporate purposes.\nThe expected use of proceeds represents the Company’s intentions based upon\nits current plans and business conditions. The Company cannot predict with\ncertainty all of the particular uses for the net proceeds to be received upon\nthe completion of the Global Offering or the amounts that the Company will\nactually spend on the uses set forth above. The amounts and timing of the\nCompany’s actual expenditures and the extent of clinical development may\nvary significantly depending on numerous factors, including the progress of\nthe development efforts, the status of and results from preclinical studies\nand any ongoing clinical trials or clinical trials the Company may commence in\nthe future, as well as any collaborations that the Company may enter into with\nthird parties for its product candidates and any unforeseen cash needs. As a\nresult, the Company’s management will retain broad discretion over the\nallocation of the net proceeds.\n\nIn connection with the Global Offering, the Company’s executive board\nmembers and supervisory board members are subject to a contractual lock-up for\na period of 90 days after the pricing of the Global Offering, subject to\ncustomary exceptions, including an exception for the purpose of financing the\nexercise price of stock options and/or satisfying any applicable taxes due in\nconnection with such exercise. The Company has also agreed to be bound by a\ncontractual lock-up for a period of 90 days after the pricing of the Global\nOffering, subject to customary exceptions.\n\nA shelf registration statement on Form F-3 (including a prospectus) relating\nto the Company’s securities was filed with the Securities and Exchange\nCommission (the “SEC”) on March 6, 2025 and subsequently declared\neffective on March 14, 2025. The Company will also file with the SEC a\npreliminary prospectus supplement (and accompanying prospectus) relating to\nand describing the terms of the Global Offering (the “Preliminary Prospectus\nSupplement”). Before purchasing ADSs, Ordinary Shares or PFW in the Global\nOffering, you should read the Preliminary Prospectus Supplement and the\naccompanying prospectus, together with the documents incorporated by reference\ntherein. You may obtain these documents for free by visiting EDGAR on the\nSEC’s website at www.sec.gov. Alternatively, a copy of the Preliminary\nProspectus Supplement (and accompanying prospectus) relating to the Global\nOffering may be obtained from Jefferies LLC, Attention: Equity Syndicate\nProspectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or\nby telephone at (877) 821-7388 or by email at\nProspectus_Department@Jefferies.com; from TD Securities (USA) LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,\nor by email at TDManualrequest@broadridge.com; or from Stifel, Nicolaus &\nCompany, Incorporated, Attention: Syndicate, One Montgomery Street, Suite\n3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at\nsyndprospectus@stifel.com.\n\nPotential investors should carefully consider the risks described under\n“Risk Factors” in the Preliminary Prospectus Supplement, including the\nfollowing risks:\n* shareholders not participating in the Global Offering may see their\nparticipation in the Company's share capital diluted due to the issuance of\nnew securities;\n* the volatility and liquidity of the Company's Ordinary Shares and ADSs may\nexperience significant fluctuation (mainly downwards), and there may be\ndifferences on Nasdaq and Euronext; and\n* sales of the Company's Ordinary Shares and ADSs, in particular by its\nsignificant shareholders, could occur on the market and have an adverse impact\non the Company's trading prices.\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext since 2012 and on the Nasdaq Global Select Market in New\nYork City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States), amongst other locations.\n\nNanobiotix is the owner of more than 25 patent families associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nContacts\n\n Nanobiotix                                                                                                                                                                                                                                                                                                    \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150  Ricky Bhajun Director, Investor Relations (EU)  investors@nanobiotix.com                                        \n Media Relations                                                                                                                                                                                                                                                                                               \n France – HARDY Caroline Hardy + 33 06 70 33 49 50 carolinehardy@outlook.fr                                                                                                              Global – uncapped Communications Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com          \n                                                                                                                                                                                                                                                                                                               \n\nSpecial Note Regarding Forward-Looking Statements\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding Nanobiotix’s proposed Global Offering and the use of proceeds\ntherefrom. Words such as “expects,” “intends,” “can,”\n“could,”, “may,” “might,” “plan,” “potential,”\n“should,” and “will,” or the negative of these and similar expressions\nare intended to identify forward-looking statements. These forward-looking\nstatements, which are based on our management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including such as market\nconditions, including the trading price and volatility of Nanobiotix’s ADSs\nand Ordinary Shares, statements regarding the completion, timing and size of\nthe Global Offering, use of net proceeds from the Global Offering and risks\nrelated to Nanobiotix’s business and financial performance. Further\ninformation on the risk factors that may affect Company business and financial\nperformance is included in Nanobiotix’s Annual Report on Form 20-F filed\nwith the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, and\nsubsequent filings Nanobiotix makes with the SEC from time to time, which are\navailable on the SEC’s website at www.sec.gov. Nanobiotix may not consummate\nthe proposed Global Offering and, if the proposed Global Offering is\nconsummated, cannot provide any assurances regarding its final terms. The\nforward-looking statements included in this press release speak only as of the\ndate of this press release, and except as required by law, Nanobiotix assumes\nno obligation to update these forward-looking statements publicly.  \n\nDisclaimers\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy any securities of the Company, nor shall there be any sale of\nsuch securities, in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nThe distribution of this press release may be subject to legal or regulatory\nrestrictions in certain jurisdictions. Any person who comes into possession of\nthis press release must inform him or herself of and comply with any such\nrestrictions.\n\nThis document does not constitute an offer to the public in France and the\nsecurities referred to in this document can only be offered or sold in France\npursuant to article L. 411-2 1° of the French Monetary and Financial Code to\nqualified investors (investisseurs qualifiés) acting for their own account as\ndefined in the Prospectus Regulation.\n\nThis announcement is an advertisement and not a prospectus within the meaning\nof the Prospectus Regulation.\n\nThe International Offering is reserved to “qualified investors”, as that\nterm is defined in Article 2(e) of the Prospectus Regulation.\n\nIn relation to each member state of the European Economic Area other than\nFrance (each, a “Relevant Member State”), an offer of the securities\nreferred to herein is not being made and will not be made to the public in\nthat Relevant Member State, other than (i) to any legal entity which is a\nqualified investor as defined in the Prospectus Regulation, (ii) to fewer than\n150 natural or legal persons per Relevant Member State; or (iii) in any other\ncircumstances falling within Article 1(4) of the Prospectus Regulation;\nprovided that no such offer of the securities referred to herein shall require\nthe Company to publish a prospectus pursuant to Article 3 of the Prospectus\nRegulation. For the purposes of the above, the expression an “offer to the\npublic” in any Relevant Member State shall have the meaning ascribed to it\nin Article 2(d) of the Prospectus Regulation.\n\nThis communication is being distributed only to, and is directed only at (a)\npersons outside the United Kingdom, (b) “qualified investors” (as defined\nin paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading\nRegulations 2024 (the “POAT Regulations”)) who have professional\nexperience in matters relating to investments falling within Article 19(5) of\nthe Financial Services and Markets Act 2000 (Financial Promotion) Order 2005\n(the “Order”), and (c) high net worth entities, and other persons to whom\nit may otherwise lawfully be communicated, falling within Article 49(2) of the\nOrder (all such persons together being referred to as “relevant persons”).\nIn the United Kingdom, any offering of securities described herein will be\nmade pursuant to an exemption under the POAT Regulations from the requirement\nto publish a prospectus. Any investment or investment activity to which this\ncommunication relates is available only to relevant persons and will be\nengaged in only with relevant persons. Any person who is not a relevant person\nshould not act or rely on this communication or any of its contents.\n\nSolely for the purposes of each manufacturer’s product approval process, the\ntarget market assessment in respect of the securities offered in the\nInternational Offering has led to the conclusion in relation to the type of\nclients criteria only that: (i) the type of clients to whom the securities are\ntargeted is eligible counterparties and professional clients only, each as\ndefined in Directive 2014/65/EU, as amended (“MiFID II”); and (ii) all\nchannels for distribution of the securities offered in the International\nOffering to eligible counterparties and professional clients are appropriate.\nAny person subsequently offering, selling or recommending the securities (a\n“distributor”) should take into consideration the manufacturers’ type of\nclients assessment; however, a distributor subject to MiFID II is responsible\nfor undertaking its own target market assessment in respect of the securities\noffered in the International Offering (by either adopting or refining the\nmanufacturers’ type of clients assessment) and determining appropriate\ndistribution channels.\n\nThis press release has been prepared in both French and English. In the event\nof any discrepancies between the two versions of the press release, the French\nlanguage version shall prevail.\n\nAttachment\n* Nano - U.S. Launch Press Release [2026 Follow-On Offering] FINALFINALPDF\n(1).pdf\n(https://ml.globenewswire.com/Resource/Download/e686ed9e-2dc6-45f9-aedd-6875aa61a366)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/36fb7b98-27d7-46cb-b989-fa31626657b8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6P6Tzh","title":"Nanobiotix Announces Launch of Global Follow-On Offering","author":"Globe Newswire","ticker":"NANOB","created":"2026-05-20T22:19:00.129Z","tickers":["NANOB"],"exchange":"Euronext Paris","article_body":"PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX\n(Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a\nlate-clinical stage biotechnology company pioneering physics-based approaches\nto expand treatment possibilities for patients with cancer and other major\ndiseases, announces the launch, subject to market and other conditions, of an\napproximately €75 million global follow-on offering (representing\napproximately $87 million) consisting of (i) a public offering of its American\nDepositary Shares (“ADSs”), each ADS representing one ordinary share,\n€0.03 nominal value per share (each an “Ordinary Share”), of the\nCompany, in the United States (the “U.S. Offering”) and (ii) an offering\nof (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for\nOrdinary Shares (the “PFW”), exclusively addressed to “qualified\ninvestors” in Europe (including France) within the meaning of Article 2(e)\nof Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”),\nand certain other countries (excluding the United States and Canada) (the\n“International Offering”). The U.S. Offering and the International\nOffering are referred to, together, as the “Global Offering”. The number\nof ADSs and Ordinary Shares issued in the Global Offering may be increased in\nthe event of significant demand.\n\nJefferies, TD Cowen and Stifel are acting as global coordinators and joint\nbookrunners for the Global Offering. The Global Offering would be subject to\nan underwriting agreement. The underwriting agreement would not constitute a\nperformance guarantee (garantie de bonne fin) within the meaning of Article L.\n225-145 of the French Commercial Code (Code de commerce).\n\nIn connection with the Global Offering, the Company intends to grant the\nunderwriters for the Global Offering a 30-day option to purchase additional\nADSs, in an amount of up to 15% of the total number of ADSs in the Global\nOffering, on the same terms and conditions, in accordance with delegation\ngranted by the Company’s combined shareholders’ meeting held on May 19,\n2025 (the “Shareholders’ Meeting”) in its 36(th) resolution.\n\nThe Ordinary Shares (including in the form of ADSs) and the PFW to be issued\nin the Global Offering will be issued without preferential subscription rights\nfor existing shareholders by way of a capital increase pursuant to the\ndelegation granted by the Shareholders’ Meeting in its 29(th) resolution.\n\nAll securities to be issued in the Global Offering will be offered by the\nCompany. The Company’s ADSs are listed on the Nasdaq Global Select Market\nunder the ticker symbol “NBTX.” The Company’s Ordinary Shares are listed\non the regulated market of Euronext in Paris (“Euronext”) under the symbol\n“NANO.” The Company does not intend to list the PFW on any domestic or\nforeign securities exchange or nationally recognized trading system.\n\nThe final amount of the Global Offering, the offering price in the U.S.\nOffering in U.S. dollars and the offering price in the International Offering\nin euros, as well as the final number of ADSs, Ordinary Shares and PFW issued\nin the Global Offering will be determined following a book-building process\ncommencing immediately. The Company will announce the results of the Global\nOffering as well as the number and subscription price of the Ordinary Shares,\nADSs and PFW to be issued in the context of the Global Offering as soon as\npracticable after pricing thereof in a subsequent press release.\n\nThe number of securities issued in the Global Offering will be determined by\nthe Company’s Executive Board in accordance with the delegations granted by\nthe Shareholders’ Meeting, pursuant to its 29(t)(h) and 39(th) resolutions.\n\nThe offering price of each Ordinary Share to be issued in the International\nOffering will be in euros and at least equal to the volume weighted average\nprice of the Ordinary Shares on Euronext over the last three trading sessions\npreceding the pricing of the Global Offering (i.e., May 18, May 19 and May 20,\n2026), subject to a maximum 15% discount. The offering price of each ADS in\nthe U.S. Offering will be the U.S. dollars equivalent of the offering price\nper Ordinary Share in euros in the International Offering.\n\nThe subscription price of each PFW to subscribe for one Ordinary Share will be\nin euros and equal to the subscription price per Ordinary Share to be paid on\nthe date of issue of the PFW, minus €0.03 to be paid on the date of exercise\nof the PFW.\n\nEach PFW will allow its holder to subscribe to one Ordinary Share at a price\nof €0.03.\n\nThe PFW are exercisable in cash during a ten-year period from their date of\nissue.\n\nThe PFW are securities giving access to the capital within the meaning of\nArticle L. 228-91 of the French Commercial Code. They will be issued in\ndematerialized form and held in pure registered form (au nominatif pur) in the\nsecurities account opened in the name of the holder thereof in the books of\nthe Company’s account keeper.\n\nNo fractional shares shall be issuable upon the exercise of PFW, provided that\nthe number of shares to be delivered in respect of any exercise of one or more\nPFW pursuant to any exercise notice shall be rounded down to the nearest whole\nmultiple of one share.\n\nIf the Company carries out any of the transactions referred to in Articles L.\n228-99 and L. 228-101 of the French Commercial Code, the rights of holders of\nthe PFW will be maintained in accordance with said articles.\n\nThe PFW will not be admitted to trading on Euronext or on any domestic or\nforeign securities exchange or nationally recognized trading system. The\nshares issued upon the exercise of PFW (the “PFW Shares”) will be held, at\nthe option of the holder, in registered form (au nominatif) or in bearer form\n(au porteur). As soon as they are issued, the PFW Shares will be automatically\nassimilated to the Company’s ordinary shares and will be admitted to trading\non Euronext under the same ISIN number.\n\nThe PFW holders will be grouped automatically for the defense of their common\ninterests in a masse. The masse will act, in part, through a representative\nand, in part, through collective decisions of the holders.\n\nOrdinary Shares (including those underlying ADS) issued in the Global Offering\nwill be subject to an application for admission to trading on Euronext on the\nsame trading line as the existing Ordinary Shares of the Company currently\nlisted on Euronext, under the same ISIN code FR0011341205. The Global Offering\nwill begin immediately following the publication of this press release and is\nexpected to price before the U.S. markets open on May 21, 2026, subject to any\nearly closing of the bookbuilding process. Following pricing of the offering\nin the United States, the trading of Nanobiotix's Ordinary Shares on Euronext\nwill be suspended on the immediately following trading day in Paris from the\nopening of Euronext until the opening of trading of Nanobiotix's ADSs on the\nNasdaq Global Select Market at approximately 3:30 pm (Paris time) / 9:30 a.m.\n(New York time) on such trading day, prior to which Nanobiotix will publish\nthe allocation of share capital to be effective following settlement and\ndelivery of the securities issued in the Global Offering.\n\nThe Company intends to use the net proceeds from the Global Offering as\nfollows:\n* less than 10% to support the development and advancement of JNJ-1900\n(NBTXR3);\n* between 50-60% to advance our Nanoprimer and other platforms; and\n* between 30-40% for general corporate purposes.\nThe expected use of proceeds represents the Company’s intentions based upon\nits current plans and business conditions. The Company cannot predict with\ncertainty all of the particular uses for the net proceeds to be received upon\nthe completion of the Global Offering or the amounts that the Company will\nactually spend on the uses set forth above. The amounts and timing of the\nCompany’s actual expenditures and the extent of clinical development may\nvary significantly depending on numerous factors, including the progress of\nthe development efforts, the status of and results from preclinical studies\nand any ongoing clinical trials or clinical trials the Company may commence in\nthe future, as well as any collaborations that the Company may enter into with\nthird parties for its product candidates and any unforeseen cash needs. As a\nresult, the Company’s management will retain broad discretion over the\nallocation of the net proceeds.\n\nIn connection with the Global Offering, the Company’s executive board\nmembers and supervisory board members are subject to a contractual lock-up for\na period of 90 days after the pricing of the Global Offering, subject to\ncustomary exceptions, including an exception for the purpose of financing the\nexercise price of stock options and/or satisfying any applicable taxes due in\nconnection with such exercise. The Company has also agreed to be bound by a\ncontractual lock-up for a period of 90 days after the pricing of the Global\nOffering, subject to customary exceptions.\n\nA shelf registration statement on Form F-3 (including a prospectus) relating\nto the Company’s securities was filed with the Securities and Exchange\nCommission (the “SEC”) on March 6, 2025 and subsequently declared\neffective on March 14, 2025. The Company will also file with the SEC a\npreliminary prospectus supplement (and accompanying prospectus) relating to\nand describing the terms of the Global Offering (the “Preliminary Prospectus\nSupplement”). Before purchasing ADSs, Ordinary Shares or PFW in the Global\nOffering, you should read the Preliminary Prospectus Supplement and the\naccompanying prospectus, together with the documents incorporated by reference\ntherein. You may obtain these documents for free by visiting EDGAR on the\nSEC’s website at www.sec.gov. Alternatively, a copy of the Preliminary\nProspectus Supplement (and accompanying prospectus) relating to the Global\nOffering may be obtained from Jefferies LLC, Attention: Equity Syndicate\nProspectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or\nby telephone at (877) 821-7388 or by email at\nProspectus_Department@Jefferies.com; from TD Securities (USA) LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,\nor by email at TDManualrequest@broadridge.com; or from Stifel, Nicolaus &\nCompany, Incorporated, Attention: Syndicate, One Montgomery Street, Suite\n3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at\nsyndprospectus@stifel.com.\n\nPotential investors should carefully consider the risks described under\n“Risk Factors” in the Preliminary Prospectus Supplement, including the\nfollowing risks:\n* shareholders not participating in the Global Offering may see their\nparticipation in the Company's share capital diluted due to the issuance of\nnew securities;\n* the volatility and liquidity of the Company's Ordinary Shares and ADSs may\nexperience significant fluctuation (mainly downwards), and there may be\ndifferences on Nasdaq and Euronext; and\n* sales of the Company's Ordinary Shares and ADSs, in particular by its\nsignificant shareholders, could occur on the market and have an adverse impact\non the Company's trading prices.\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext since 2012 and on the Nasdaq Global Select Market in New\nYork City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States), amongst other locations.\n\nNanobiotix is the owner of more than 25 patent families associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nContacts\n\n Nanobiotix                                                                                                                                                                                                                                                                                                    \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150  Ricky Bhajun Director, Investor Relations (EU)  investors@nanobiotix.com                                        \n Media Relations                                                                                                                                                                                                                                                                                               \n France – HARDY Caroline Hardy + 33 06 70 33 49 50 carolinehardy@outlook.fr                                                                                                              Global – uncapped Communications Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com          \n                                                                                                                                                                                                                                                                                                               \n\nSpecial Note Regarding Forward-Looking Statements\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding Nanobiotix’s proposed Global Offering and the use of proceeds\ntherefrom. Words such as “expects,” “intends,” “can,”\n“could,”, “may,” “might,” “plan,” “potential,”\n“should,” and “will,” or the negative of these and similar expressions\nare intended to identify forward-looking statements. These forward-looking\nstatements, which are based on our management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including such as market\nconditions, including the trading price and volatility of Nanobiotix’s ADSs\nand Ordinary Shares, statements regarding the completion, timing and size of\nthe Global Offering, use of net proceeds from the Global Offering and risks\nrelated to Nanobiotix’s business and financial performance. Further\ninformation on the risk factors that may affect Company business and financial\nperformance is included in Nanobiotix’s Annual Report on Form 20-F filed\nwith the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, and\nsubsequent filings Nanobiotix makes with the SEC from time to time, which are\navailable on the SEC’s website at www.sec.gov. Nanobiotix may not consummate\nthe proposed Global Offering and, if the proposed Global Offering is\nconsummated, cannot provide any assurances regarding its final terms. The\nforward-looking statements included in this press release speak only as of the\ndate of this press release, and except as required by law, Nanobiotix assumes\nno obligation to update these forward-looking statements publicly.  \n\nDisclaimers\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy any securities of the Company, nor shall there be any sale of\nsuch securities, in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nThe distribution of this press release may be subject to legal or regulatory\nrestrictions in certain jurisdictions. Any person who comes into possession of\nthis press release must inform him or herself of and comply with any such\nrestrictions.\n\nThis document does not constitute an offer to the public in France and the\nsecurities referred to in this document can only be offered or sold in France\npursuant to article L. 411-2 1° of the French Monetary and Financial Code to\nqualified investors (investisseurs qualifiés) acting for their own account as\ndefined in the Prospectus Regulation.\n\nThis announcement is an advertisement and not a prospectus within the meaning\nof the Prospectus Regulation.\n\nThe International Offering is reserved to “qualified investors”, as that\nterm is defined in Article 2(e) of the Prospectus Regulation.\n\nIn relation to each member state of the European Economic Area other than\nFrance (each, a “Relevant Member State”), an offer of the securities\nreferred to herein is not being made and will not be made to the public in\nthat Relevant Member State, other than (i) to any legal entity which is a\nqualified investor as defined in the Prospectus Regulation, (ii) to fewer than\n150 natural or legal persons per Relevant Member State; or (iii) in any other\ncircumstances falling within Article 1(4) of the Prospectus Regulation;\nprovided that no such offer of the securities referred to herein shall require\nthe Company to publish a prospectus pursuant to Article 3 of the Prospectus\nRegulation. For the purposes of the above, the expression an “offer to the\npublic” in any Relevant Member State shall have the meaning ascribed to it\nin Article 2(d) of the Prospectus Regulation.\n\nThis communication is being distributed only to, and is directed only at (a)\npersons outside the United Kingdom, (b) “qualified investors” (as defined\nin paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading\nRegulations 2024 (the “POAT Regulations”)) who have professional\nexperience in matters relating to investments falling within Article 19(5) of\nthe Financial Services and Markets Act 2000 (Financial Promotion) Order 2005\n(the “Order”), and (c) high net worth entities, and other persons to whom\nit may otherwise lawfully be communicated, falling within Article 49(2) of the\nOrder (all such persons together being referred to as “relevant persons”).\nIn the United Kingdom, any offering of securities described herein will be\nmade pursuant to an exemption under the POAT Regulations from the requirement\nto publish a prospectus. Any investment or investment activity to which this\ncommunication relates is available only to relevant persons and will be\nengaged in only with relevant persons. Any person who is not a relevant person\nshould not act or rely on this communication or any of its contents.\n\nSolely for the purposes of each manufacturer’s product approval process, the\ntarget market assessment in respect of the securities offered in the\nInternational Offering has led to the conclusion in relation to the type of\nclients criteria only that: (i) the type of clients to whom the securities are\ntargeted is eligible counterparties and professional clients only, each as\ndefined in Directive 2014/65/EU, as amended (“MiFID II”); and (ii) all\nchannels for distribution of the securities offered in the International\nOffering to eligible counterparties and professional clients are appropriate.\nAny person subsequently offering, selling or recommending the securities (a\n“distributor”) should take into consideration the manufacturers’ type of\nclients assessment; however, a distributor subject to MiFID II is responsible\nfor undertaking its own target market assessment in respect of the securities\noffered in the International Offering (by either adopting or refining the\nmanufacturers’ type of clients assessment) and determining appropriate\ndistribution channels.\n\nThis press release has been prepared in both French and English. In the event\nof any discrepancies between the two versions of the press release, the French\nlanguage version shall prevail.\n\nAttachment\n* Nano - U.S. Launch Press Release [2026 Follow-On Offering] FINALFINALPDF\n(1).pdf\n(https://ml.globenewswire.com/Resource/Download/e686ed9e-2dc6-45f9-aedd-6875aa61a366)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/36fb7b98-27d7-46cb-b989-fa31626657b8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-20T22:19:00.186079003Z","server_sent_at_ms":1779315540186},"received_at":"2026-05-20T22:19:00.348Z","source_url":null},"analysis":{"id":"30850","press_release_id":"41411","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Dilutive issuance of new shares and pre-funded warrants","30-40% of proceeds allocated to 'general corporate purposes'","International offering price may include up to 15% discount to VWAP"],"eventType":"offering","narrative":"Nanobiotix launched a global follow-on offering of approximately €75 million ($87 million) to raise capital for clinical development and general corporate purposes.\n\nThe offering consists of a U.S. public offering of ADSs and an international offering of ordinary shares and pre-funded warrants (PFW) to qualified investors in Europe.\n\nProceeds will be allocated with 50-60% to advance the Nanoprimer platform, less than 10% to support JNJ-1900 (NBTXR3), and 30-40% for general corporate purposes.\n\nExisting shareholders face dilution from the new issuance, and insiders are subject to a 90-day lock-up following pricing.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Nanobiotix raises $87M via dilutive follow-on offering; watch for price discovery and discount levels in the international tranche."},"keyFigures":{"dealValueUsd":87000000,"customDimensions":{"pfw_tenor":"10 years","dealValueEur":"€75 million","lockup_period":"90 days","pfw_exercise_price":"€0.03","oversubscription_option":"15%"}},"quotedText":"The Company intends to use the net proceeds from the Global Offering as follows: less than 10% to support the development and advancement of JNJ-1900 (NBTXR3); between 50-60% to advance our Nanoprimer and other platforms; and between 30-40% for general corporate purposes.","namedEntities":{"people":[{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900","NBTXR3","Nanoprimer"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Jefferies","relationship":"underwriter"},{"name":"TD Cowen","relationship":"underwriter"},{"name":"Stifel","relationship":"underwriter"}],"dollarAmounts":[{"amount":"€75 million","context":"Global follow-on offering size in EUR"},{"amount":"$87 million","context":"Global follow-on offering size in USD"},{"amount":"€0.03","context":"Nominal value per share / PFW exercise price"}]},"materialImpact":{"score":4,"reasoning":"Launch of a ~$87M global follow-on offering. While proceeds support clinical development (JNJ-1900/NBTXR3) and platform advancement, the issuance of new shares and pre-funded warrants creates immediate dilution for existing shareholders. The potential for a discount in the International Offering and the 'general corporate purposes' allocation add downside risk."},"tickerRelevance":{"others":[{"ticker":"NBTX","relevance":"primary_listing"}],"primary":"NANOB"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"dilutive_capital_raise","sectorWeight":"biotech_high_interest","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":4,"narrative":"Nanobiotix launched a global follow-on offering of approximately €75 million ($87 million) to raise capital for clinical development and general corporate purposes.\n\nThe offering consists of a U.S. public offering of ADSs and an international offering of ordinary shares and pre-funded warrants (PFW) to qualified investors in Europe.\n\nProceeds will be allocated with 50-60% to advance the Nanoprimer platform, less than 10% to support JNJ-1900 (NBTXR3), and 30-40% for general corporate purposes.\n\nExisting shareholders face dilution from the new issuance, and insiders are subject to a 90-day lock-up following pricing.","key_figures":{"dealValueUsd":87000000,"customDimensions":{"pfw_tenor":"10 years","dealValueEur":"€75 million","lockup_period":"90 days","pfw_exercise_price":"€0.03","oversubscription_option":"15%"}},"named_entities":{"people":[{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900","NBTXR3","Nanoprimer"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Jefferies","relationship":"underwriter"},{"name":"TD Cowen","relationship":"underwriter"},{"name":"Stifel","relationship":"underwriter"}],"dollarAmounts":[{"amount":"€75 million","context":"Global follow-on offering size in EUR"},{"amount":"$87 million","context":"Global follow-on offering size in USD"},{"amount":"€0.03","context":"Nominal value per share / PFW exercise price"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-20T22:19:19.653Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"dilutive_capital_raise","sectorWeight":"biotech_high_interest","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":19294,"modelName":"george-droid-qwen-72b"}}